In School + On Track: Attorney General's Report on California's Elementary School Truancy and Absenteeism Crisis

This report is the first to present state-wide statistics on California's truancy crisis which reveal that, last year alone, 1 million elementary school students were truant and 250,000 elementary school students missed 18 or more school days at a cost of $1.4 billion in lost funds to California school districts.This report was issued by Attorney General Kamala D. Harris, after a meeting where statewide education, public policy and law enforcement leaders were convened to discuss this crisis and identify concrete solutions."The California Constitution guarantees every child the right to an education, yet we are failing our youngest children, as early as kindergarten," Attorney General Harris said. "These are children as young as five years old who are out of school, falling behind, and too many of them never catch up. This crisis is not only crippling for our economy, it is a basic threat to public safety. It's time for accountability and to craft real solutions at every level - from parents to school districts, to law enforcement - to solve this problem."According to the report, elementary school truancy is at the root of the state's chronic criminal justice problems. According to the report, missing large amounts of school is one of the strongest predictors of dropping-out, even more so than suspensions or test scores. Annually, dropouts cost California taxpayers an estimated$46.4 billion in incarceration, lost productivity and lost taxes

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)